[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl] hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl] hydrogen phosphate
• 化学式: C₁₀H₁₈N₅O₂₀P₅
• 分子量: 683.14
• InChiKey: FXVGNAQPBLWYFQ-UUOKFMHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.7
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  388
• 氢给体数：
  10
• 氢受体数：
  21

文献信息

• [EN] RELA INHIBITORS FOR BIOFILM DISRUPTION<br/>[FR] INHIBITEURS DE RELA POUR LA RUPTURE D'UN BIOFILM
  申请人：UNIV DREXEL

  公开号：WO2018213185A1

  公开（公告）日：2018-11-22

  Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.

  药物组合物包括RelA酶抑制剂和杀菌性抗生素，其中所述的RelA酶抑制剂与细菌中的RelA酶结合，以减少生物膜的形成并分解已形成的生物膜。该药物组合物可用于治疗细菌生物膜疾病。
• Synthesis and use of anti-reverse mRBA cap analogues
  申请人：——

  公开号：US20030194759A1

  公开（公告）日：2003-10-16

  The ability to synthesize capped RNA transcripts in vitro has been of considerable value in a variety of applications. However, one-third to one-half of the caps have, until now, been incorporated in the reverse orientation. Such reverse caps impair the translation of in vitro-synthesized mRNAs. Novel cap analogues, such as P 1 -3′-deoxy-7-methylguanosine-5′P 3 -guanosine-5′triphosphate and P 1 -3′-O,7-dimethylguanosine-5′P 3 -guanosine-5′triphosphate, have been designed that are incapable of being incorporated into RNA in the reverse orientation. Transcripts produced with SP6 polymerase using “anti-reverse” cap analogues were of the predicted length. Analysis of the transcripts indicated that reverse caps were not formed. The in vitro translational efficiency of transcripts with the novel “anti-reverse” cap analogues was significantly higher than that of transcripts formed with conventional caps.

  在体外合成带帽RNA转录本的能力在各种应用中具有相当的价值。然而，直到现在，三分之一到一半的帽子都是以反向方向合并的。这种反向帽子会影响体外合成的mRNA的翻译。已经设计出了新的帽子类似物，例如P1-3'-去氧-7-甲基鸟嘌呤-5'P3-鸟嘌呤-5'三磷酸和P1-3'-O，7-二甲基鸟嘌呤-5'P3-鸟嘌呤-5'三磷酸，它们不能以反向方向被合并到RNA中。使用“反向”帽子类似物的SP6聚合酶产生的转录本长度与预期相同。转录本的分析表明没有形成反向帽子。具有新的“反向”帽子类似物的转录本的体外翻译效率显着高于使用传统帽子形成的转录本。
• Synthesis and use of anti-reverse mRNA cap analogues
  申请人：Darzynkiewicz Edward

  公开号：US20060252115A1

  公开（公告）日：2006-11-09

  The ability to synthesize capped RNA transcripts in vitro has been of considerable value in a variety of applications. However, one-third to one-half of the caps have, until now, been incorporated in the reverse orientation. Such reverse caps impair the translation of in vitro-synthesized mRNAs. Novel cap analogues, such as P 1 -3′-deoxy-7-methylguanosine-5′ P 3 -guanosine-5′ triphosphate and P 1 -3′-O,7-dimethylguanosine-5′ P 3 -guanosine-5′ triphosphate, have been designed that are incapable of being incorporated into RNA in the reverse orientation. Transcripts produced with SP6 polymerase using “anti-reverse” cap analogues were of the predicted length. Analysis of the transcripts indicated that reverse caps were not formed. The in vitro translational efficiency of transcripts with the novel “anti-reverse” cap analogues was significantly higher than that of transcripts formed with conventional caps.

  在体外合成带帽RNA转录本的能力在各种应用中具有相当的价值。然而，到目前为止，三分之一到一半的帽子是以反向方向合并的。这些反向帽子会影响体外合成的mRNA的翻译。设计了新的帽子类似物，例如P1-3'-去氧-7-甲基鸟嘌呤-5' P3-鸟嘌呤-5' 三磷酸酯和P1-3'-O，7-二甲基鸟嘌呤-5' P3-鸟嘌呤-5' 三磷酸酯，这些类似物无法以反向方向被合并到RNA中。使用“抗反向”帽子类似物的SP6聚合酶产生的转录本长度与预测长度相同。对转录本的分析表明，没有形成反向帽子。使用新型“抗反向”帽子类似物形成的转录本的体外翻译效率显著高于使用常规帽子形成的转录本。
• Methods and means for metabolic engineering and improved product formation by micro-organisms
  申请人：Universiteit Leiden

  公开号：EP1818398A1

  公开（公告）日：2007-08-15

  The invention relates to the field of biochemistry, molecular biology and microbiology. More specific the invention relates to methods and means for metabolic engineering and improved product formation by a filamentous micro-organism or a low G+C gram-positive bacterium. The invention discloses that DasR and DasR binding sites play an important and universal role in the control of gene expression in microorganisms Based on this finding, the invention provides multiple useful applications, such as a method for regulating the expression of a gene of interest, a method for controlling metabolism, a method for decreasing undesired expression and many more. Moreover, the invention also provides means that can be used to establish said methods: for example a micro-organism in which the DasR binding site in operable linkage with a particular gene has been modified to obtain increased or decreased expression of a protein (being a desired or undesired protein) encoded by said gene.

  本发明涉及生物化学、分子生物学和微生物学领域。更具体地说，本发明涉及丝状微生物或低 G+C 革兰氏阳性菌的代谢工程和改良产品形成的方法和手段。 本发明公开了 DasR 和 DasR 结合位点在控制微生物基因表达中的重要和普遍作用。 基于这一发现，本发明提供了多种有用的应用，如调节相关基因表达的方法、控制新陈代谢的方法、减少不良表达的方法等等。此外，本发明还提供了可用于建立上述方法的手段：例如，对微生物中与特定基因可操作连接的 DasR 结合位点进行修饰，以增加或减少由所述基因编码的蛋白质（期望的或不期望的蛋白质）的表达。
• Accumulation of metabolic products in bacterial microcompartments
  申请人：University College Cork

  公开号：EP2574620A1

  公开（公告）日：2013-04-03

  A non-therapeutic method of accumulating a polymeric or high molecular weight molecular product within a bacterial microcompartment in bacterial cytoplasm, which method employs a recombinant bacteria which is genetically engineered to express a microcompartment containing an enzyme capable of converting a low molecular weight substrate into a polymeric or high molecular weight product, the method comprising the steps of: incubating the recombinant bacteria with the low-molecular weight substrate, or a precursor of the low molecular weight substrate which is capable of being metabolised to the substrate within the recombinant bacteria, such that the substrate or precursor is taken up by the bacteria, wherein the substrate enters the microcompartment and the enzyme within the microcompartment converts the substrate to a polymeric or high molecular weight molecular product, and wherein the polymeric or high molecular weight molecular product is accumulated within the microcompartment due to its size.

  一种在细菌细胞质的细菌微室中积累聚合物或高分子量分子产物的非治疗性方法，该方法采用一种重组细菌，该细菌经基因工程改造，表达一种含有能将低分子量底物转化为聚合物或高分子量产物的酶的微室，该方法包括以下步骤：将重组细菌与低分子量底物或能够在重组细菌内代谢为底物的低分子量底物的前体一起培养，使底物或前体被细菌吸收，其中底物进入微室，微室内的酶将底物转化为聚合物或高分子量分子产物，其中聚合物或高分子量分子产物因其大小而在微室内积累。